Response to Reinhardt et al.

Human Gene Therapy

Volumn 22, Issue 6, 2011, Pages 776-

  Sensebé, Luc ^a,b   Bourin, Philippe ^a,b   Tarte, Karin ^a,c  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FETAL BOVINE SERUM; LETTER; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; MESENCHYME CELL; NONHUMAN; SERUM; STROMA CELL;

EID: 79958239592     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.2502     Document Type: Letter

References (4)

1. Horwitz, E.M., Gordon, P.L., Koo, W.K., et al. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imper-fecta: Implications for cell therapy of bone. Proc. Natl. Acad. Sci. U.S.A. 99, 8932-8937. (Pubitemid 34693661)
2. Sensebé, L., Bourin, P., and Tarte, K. (2011). Good Manufacturing Practices production of mesenchymal stem/stromal cells. Hum. Gene Ther. 22, 19-26.
3. Spees, J.L., Gregory, C.A., Singh, H., et al. (2004). Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol. Ther. 9, 747-756. (Pubitemid 38660428)
4. Sundin, M., Ringden, O., Sundberg, B., et al. (2007). No alloan-tibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allo-geneic hematopoietic stem cell recipients. Haematologica 92, 1208-1215. (Pubitemid 350144179)